Importantly, inhibition of RhoA-SRF-MRTFA pathway by CCG-1423 reversed Nogo-B-induced cancer progression, demonstrating that CCG-1423 may be a potential target drug of NPC. The gene discussed is SRF; the disease is nasopharyngeal carcinoma.